VRTX

Vertex Pharmaceuticals Incorporated Press Releases

$118.9
*  
1.16
0.99%
Get VRTX Alerts
*Delayed - data as of Dec. 19, 2014  -  Find a broker to begin trading VRTX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Exelis to provide radar signal simulators to U.S. Air Force
12/15/2014 9:00:00 AM - Business Wire


David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer
12/15/2014 9:00:00 AM - Business Wire
▼-0.09 % Price Change since this news event. The Volume Ratio is 1.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Vertex to Present at Deutsche Bank BioFEST on December 2
11/20/2014 4:01:00 PM - Business Wire


Cystic Fibrosis Foundation Royalty Sale Will Be Transformational for People with CF
11/19/2014 9:03:00 AM - PR Newswire


Royalty Pharma Announces $3.3 Billion Royalty Transaction with Cystic Fibrosis Foundation Therapeutics
11/19/2014 7:22:00 AM - PR Newswire


Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
11/5/2014 7:00:00 AM - Business Wire
▲4.21 % Price Change since this news event. The Volume Ratio is 0.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Vertex to Present at the Credit Suisse Healthcare Conference on November 11
10/30/2014 4:01:00 PM - Business Wire
▲7.26 % Price Change since this news event. The Volume Ratio is 0.99.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Vertex Reports Third Quarter 2014 Financial Results
10/28/2014 4:01:00 PM - Business Wire
▲4.34 % Price Change since this news event. The Volume Ratio is 1.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation
10/21/2014 4:47:00 PM - Business Wire
▲9.18 % Price Change since this news event. The Volume Ratio is 0.87.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Vertex to Announce Third Quarter 2014 Financial Results on October 28
10/14/2014 4:01:00 PM - Business Wire
▲14.04 % Price Change since this news event. The Volume Ratio is 1.36.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis
10/9/2014 9:32:00 AM - Business Wire
▲11.84 % Price Change since this news event. The Volume Ratio is 0.94.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day